Determinants of Patient Mobility for Radical Prostate Cancer Radiation Therapy in the Precision Medicine Era: A Population-Based Study of Choice and Competition in England

Ajay Aggarwal(King's College London), Jan van der Meulen(London School of Hygiene & Tropical Medicine), Malcolm D. Mason(Royal Marsden Hospital), Richard Sullivan(Precision Spine (United States)), Arunan Sujenthiran(Royal College of Surgeons of England), Susan C. Charman(MRC Biostatistics Unit), Daniel Lewis(The Huntington Library, Art Museum, and Botanical Gardens)
International Journal of Radiation Oncology*Biology*Physics
September 23, 2017
10.1016/j.ijrobp.2017.06.1532
Cited by 2

Related Papers

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
|The Lancet|2015|2k
The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study
|The Lancet Oncology|2020|1.9k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k
The Lancet Commission on diagnostics: transforming access to diagnostics
|The Lancet|2021|442
Age, chronic disease, sepsis, organ system failure, and mortality in a medical intensive care unit
|Critical Care Medicine|1990|368